Compare SBI & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBI | ABOS |
|---|---|---|
| Founded | 1992 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.7M | 113.9M |
| IPO Year | N/A | 2021 |
| Metric | SBI | ABOS |
|---|---|---|
| Price | $7.76 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 39.5K | ★ 145.4K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.96 | $0.86 |
| 52 Week High | $8.00 | $2.46 |
| Indicator | SBI | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 60.73 |
| Support Level | $7.76 | $1.87 |
| Resistance Level | $7.84 | $2.02 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 46.67 | 91.38 |
Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.